We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+12.55%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.14B
AUM Growth
+$2.89M
Cap. Flow
-$226M
Cap. Flow %
-10.56%
Top 10 Hldgs %
48.86%
Holding
120
New
11
Increased
17
Reduced
24
Closed
24

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$45.5M
2
SHPG
Shire pic
SHPG
+$33.6M
3
MDRX
Veradigm Inc. Common Stock
MDRX
+$20.4M
4
NPSP
NPS PHARMACEUTICALS INC
NPSP
+$11.6M
5
VTR icon
Ventas
VTR
+$10.8M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$42.4M
2
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$32.8M
3
ILMN icon
Illumina
ILMN
+$22.7M
4
AMGN icon
Amgen
AMGN
+$20.2M
5
IPXL
Impax Laboratories, Inc.
IPXL
+$18.9M

Sector Composition

Rank Sector Weight
1 Healthcare 85.4%
2 Real Estate 4.1%
3 Financials 1.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LGND icon
76
Ligand Pharmaceuticals
LGND
$5.76B
$3.68M 0.17%
110,928
– –
BDSI
77
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$3.41M 0.16%
283,411
-218,142
-43% -$3.31M
IPCI
78
DELISTED
Intellipharmaceuticals International Inc.
IPCI
$3.17M 0.15%
140,400
– –
DRNA
79
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$2.57M 0.12%
+156,250
New +$1.8M
RCPT
80
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$2.5M 0.12%
+20,400
New +$2.07M
SRNE
81
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$2.15M 0.1%
+213,896
New +$1.08M
SGNT
82
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
$2.15M 0.1%
85,500
-319,231
-79% -$9.36M
BLCM
83
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$1.38M 0.06%
+6,000
New +$1.29M
LITS
84
Lite Strategy Inc
LITS
$32.8M
$1.04M 0.05%
12,196
– –
LRMR icon
85
Larimar Therapeutics
LRMR
$397M
$821K 0.04%
+2,218
New +$572K
MGNX icon
86
MacroGenics
MGNX
$235M
$447K 0.02%
12,743
-19,114
-60% -$476K
ACHV icon
87
Achieve Life Sciences
ACHV
$659M
$259K 0.01%
51
– –
SAGE
88
DELISTED
Sage Therapeutics
SAGE
$183K 0.01%
5,000
– –
GILD icon
89
CALL
Gilead Sciences
GILD
$162B
$91K ﹤0.01%
961
-159,939
-99% -$16.5M
JAZZ icon
90
CALL
Jazz Pharmaceuticals
JAZZ
$15.9B
$46K ﹤0.01%
+281
New +$46.6K
REGN icon
91
CALL
Regeneron Pharmaceuticals
REGN
$78.5B
$46K ﹤0.01%
+112
New +$44K
AMGN icon
92
CALL
Amgen
AMGN
$208B
$45K ﹤0.01%
+285
New +$44.4K
CLVS
93
DELISTED
Clovis Oncology, Inc.
CLVS
$3K ﹤0.01%
51
-104,000
-100% -$5.47M
ALGN icon
94
Align Technology
ALGN
$12.1B
– –
-70,400
Closed -$3.64M
AMRN
95
Amarin Corp
AMRN
$299M
– –
-282,171
Closed -$6.15M
BIIB icon
96
CALL
Biogen
BIIB
$30B
– –
-12,800
Closed -$4.23M
BLUE
97
CALL
DELISTED
bluebird bio
BLUE
– –
-9,140
Closed -$4.25M
CLDX icon
98
CALL
Celldex Therapeutics
CLDX
$2.99B
– –
-33,893
Closed -$6.59M
CLDX icon
99
Celldex Therapeutics
CLDX
$2.99B
– –
-33,893
Closed -$6.59M
ILMN icon
100
CALL
Illumina
ILMN
$31B
– –
-24,261
Closed -$3.87M
1 2 3
4
5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2014 Portfolio in Review

As of Q4 2014, Tekla Capital Management held 120 positions worth $2.14B, up 0.14% from $2.13B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Tekla Capital Management withdrew a net $226M in Q4 2014, closing 24 positions and reducing 24 holdings. Its most notable exit was CUBIST PHARMACEUTICALS INC, an estimated $32.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 82% a quarter earlier, followed by Real Estate and Financials.

Against the trend, Tekla Capital Management opened a new position in Veradigm Inc. Common Stock worth $20.5M.

  • Tekla Capital Management's largest Q4 2014 buy was Veradigm Inc. Common Stock: 1,604,600 shares worth $20.5M.
  • Tekla Capital Management added most to Biogen in Q4 2014, an estimated $45.5M increase.
  • Tekla Capital Management's biggest Q4 2014 reduction was Gilead Sciences, cutting an estimated $42.4M.
  • Tekla Capital Management fully exited CUBIST PHARMACEUTICALS INC in Q4 2014, selling an estimated $32.8M.
  • Tekla Capital Management's ten largest holdings make up 49% of its $2.14B portfolio in Q4 2014.
  • Tekla Capital Management opened 11 new positions and closed 24 in Q4 2014.
  • Tekla Capital Management's portfolio value rose 0.14% quarter-over-quarter to $2.14B.

Based on Tekla Capital Management's 13F filing for Q4 2014, filed 30 Jan 2015.